Loading clinical trials...
Loading clinical trials...
A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)
Conditions
Interventions
CFZ533
Placebo
Locations
71
United States
Novartis Investigative Site
Duluth, Georgia, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Baton Rouge, Louisiana, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Mineola, New York, United States
Start Date
October 1, 2019
Primary Completion Date
September 28, 2022
Completion Date
June 6, 2023
Last Updated
September 15, 2023
NCT06440525
NCT06528197
NCT03614299
NCT04093531
NCT06049368
NCT04035668
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions